Cargando…
Epidemiological and Clinical Features of SARS-CoV-2 Variants Circulating between April–December 2021 in Italy
SARS-CoV-2 is constantly evolving, leading to new variants. We analysed data from 4400 SARS-CoV-2-positive samples in order to pursue epidemiological variant surveillance and to evaluate their impact on public health in Italy in the period of April–December 2021. The main circulating strain (76.2%)...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9699621/ https://www.ncbi.nlm.nih.gov/pubmed/36423117 http://dx.doi.org/10.3390/v14112508 |
_version_ | 1784839119269003264 |
---|---|
author | Lai, Alessia Bergna, Annalisa Della Ventura, Carla Menzo, Stefano Bruzzone, Bianca Sagradi, Fabio Ceccherini-Silberstein, Francesca Weisz, Alessandro Clementi, Nicola Brindicci, Gaetano Vicenti, Ilaria Sasset, Lolita Caucci, Sara Corvaro, Benedetta Ippoliti, Silvia Acciarri, Carla De Pace, Vanessa Lanfranchi, Leonardo Bellocchi, Maria C. Giurato, Giorgio Ferrarese, Roberto Lagioia, Antonella Francisci, Daniela Colombo, Martina L. Lazzarin, Samuel Ogliastro, Matilde Cappelletti, Maria R. Iannetta, Marco Rizzo, Francesca Torti, Carlo Fumi, Maurizio d’Avenia, Morena Brusa, Stefano Greco, Francesca Menchise, Angela Letizia, Vittoria Vaccaro, Emilia Santoro, Carmen R. Fraccalvieri, Chiara Testa, Sophie Carioti, Luca Rocco, Teresa Saracino, Annalisa Cattelan, Annamaria Clementi, Massimo Sarmati, Loredana Riva, Agostino Galli, Massimo Antinori, Spinello Zehender, Gianguglielmo |
author_facet | Lai, Alessia Bergna, Annalisa Della Ventura, Carla Menzo, Stefano Bruzzone, Bianca Sagradi, Fabio Ceccherini-Silberstein, Francesca Weisz, Alessandro Clementi, Nicola Brindicci, Gaetano Vicenti, Ilaria Sasset, Lolita Caucci, Sara Corvaro, Benedetta Ippoliti, Silvia Acciarri, Carla De Pace, Vanessa Lanfranchi, Leonardo Bellocchi, Maria C. Giurato, Giorgio Ferrarese, Roberto Lagioia, Antonella Francisci, Daniela Colombo, Martina L. Lazzarin, Samuel Ogliastro, Matilde Cappelletti, Maria R. Iannetta, Marco Rizzo, Francesca Torti, Carlo Fumi, Maurizio d’Avenia, Morena Brusa, Stefano Greco, Francesca Menchise, Angela Letizia, Vittoria Vaccaro, Emilia Santoro, Carmen R. Fraccalvieri, Chiara Testa, Sophie Carioti, Luca Rocco, Teresa Saracino, Annalisa Cattelan, Annamaria Clementi, Massimo Sarmati, Loredana Riva, Agostino Galli, Massimo Antinori, Spinello Zehender, Gianguglielmo |
author_sort | Lai, Alessia |
collection | PubMed |
description | SARS-CoV-2 is constantly evolving, leading to new variants. We analysed data from 4400 SARS-CoV-2-positive samples in order to pursue epidemiological variant surveillance and to evaluate their impact on public health in Italy in the period of April–December 2021. The main circulating strain (76.2%) was the Delta variant, followed by the Alpha (13.3%), the Omicron (5.3%), and the Gamma variants (2.9%). The B.1.1 lineages, Eta, Beta, Iota, Mu, and Kappa variants, represented around 1% of cases. There were 48.2% of subjects who had not been vaccinated, and they had a lower median age compared to the vaccinated subjects (47 vs. 61 years). An increasing number of infections in the vaccinated subjects were observed over time, with the highest proportion in November (85.2%). The variants correlated with clinical status; the largest proportion of symptomatic patients (59.6%) was observed with the Delta variant, while subjects harbouring the Gamma variant showed the highest proportion of asymptomatic infection (21.6%), albeit also deaths (5.4%). The Omicron variant was only found in the vaccinated subjects, of which 47% had been hospitalised. The diffusivity and pathogenicity associated with the different SARS-CoV-2 variants are likely to have relevant public health implications, both at the national and international levels. Our study provides data on the rapid changes in the epidemiological landscape of the SARS-CoV-2 variants in Italy. |
format | Online Article Text |
id | pubmed-9699621 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-96996212022-11-26 Epidemiological and Clinical Features of SARS-CoV-2 Variants Circulating between April–December 2021 in Italy Lai, Alessia Bergna, Annalisa Della Ventura, Carla Menzo, Stefano Bruzzone, Bianca Sagradi, Fabio Ceccherini-Silberstein, Francesca Weisz, Alessandro Clementi, Nicola Brindicci, Gaetano Vicenti, Ilaria Sasset, Lolita Caucci, Sara Corvaro, Benedetta Ippoliti, Silvia Acciarri, Carla De Pace, Vanessa Lanfranchi, Leonardo Bellocchi, Maria C. Giurato, Giorgio Ferrarese, Roberto Lagioia, Antonella Francisci, Daniela Colombo, Martina L. Lazzarin, Samuel Ogliastro, Matilde Cappelletti, Maria R. Iannetta, Marco Rizzo, Francesca Torti, Carlo Fumi, Maurizio d’Avenia, Morena Brusa, Stefano Greco, Francesca Menchise, Angela Letizia, Vittoria Vaccaro, Emilia Santoro, Carmen R. Fraccalvieri, Chiara Testa, Sophie Carioti, Luca Rocco, Teresa Saracino, Annalisa Cattelan, Annamaria Clementi, Massimo Sarmati, Loredana Riva, Agostino Galli, Massimo Antinori, Spinello Zehender, Gianguglielmo Viruses Article SARS-CoV-2 is constantly evolving, leading to new variants. We analysed data from 4400 SARS-CoV-2-positive samples in order to pursue epidemiological variant surveillance and to evaluate their impact on public health in Italy in the period of April–December 2021. The main circulating strain (76.2%) was the Delta variant, followed by the Alpha (13.3%), the Omicron (5.3%), and the Gamma variants (2.9%). The B.1.1 lineages, Eta, Beta, Iota, Mu, and Kappa variants, represented around 1% of cases. There were 48.2% of subjects who had not been vaccinated, and they had a lower median age compared to the vaccinated subjects (47 vs. 61 years). An increasing number of infections in the vaccinated subjects were observed over time, with the highest proportion in November (85.2%). The variants correlated with clinical status; the largest proportion of symptomatic patients (59.6%) was observed with the Delta variant, while subjects harbouring the Gamma variant showed the highest proportion of asymptomatic infection (21.6%), albeit also deaths (5.4%). The Omicron variant was only found in the vaccinated subjects, of which 47% had been hospitalised. The diffusivity and pathogenicity associated with the different SARS-CoV-2 variants are likely to have relevant public health implications, both at the national and international levels. Our study provides data on the rapid changes in the epidemiological landscape of the SARS-CoV-2 variants in Italy. MDPI 2022-11-12 /pmc/articles/PMC9699621/ /pubmed/36423117 http://dx.doi.org/10.3390/v14112508 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Lai, Alessia Bergna, Annalisa Della Ventura, Carla Menzo, Stefano Bruzzone, Bianca Sagradi, Fabio Ceccherini-Silberstein, Francesca Weisz, Alessandro Clementi, Nicola Brindicci, Gaetano Vicenti, Ilaria Sasset, Lolita Caucci, Sara Corvaro, Benedetta Ippoliti, Silvia Acciarri, Carla De Pace, Vanessa Lanfranchi, Leonardo Bellocchi, Maria C. Giurato, Giorgio Ferrarese, Roberto Lagioia, Antonella Francisci, Daniela Colombo, Martina L. Lazzarin, Samuel Ogliastro, Matilde Cappelletti, Maria R. Iannetta, Marco Rizzo, Francesca Torti, Carlo Fumi, Maurizio d’Avenia, Morena Brusa, Stefano Greco, Francesca Menchise, Angela Letizia, Vittoria Vaccaro, Emilia Santoro, Carmen R. Fraccalvieri, Chiara Testa, Sophie Carioti, Luca Rocco, Teresa Saracino, Annalisa Cattelan, Annamaria Clementi, Massimo Sarmati, Loredana Riva, Agostino Galli, Massimo Antinori, Spinello Zehender, Gianguglielmo Epidemiological and Clinical Features of SARS-CoV-2 Variants Circulating between April–December 2021 in Italy |
title | Epidemiological and Clinical Features of SARS-CoV-2 Variants Circulating between April–December 2021 in Italy |
title_full | Epidemiological and Clinical Features of SARS-CoV-2 Variants Circulating between April–December 2021 in Italy |
title_fullStr | Epidemiological and Clinical Features of SARS-CoV-2 Variants Circulating between April–December 2021 in Italy |
title_full_unstemmed | Epidemiological and Clinical Features of SARS-CoV-2 Variants Circulating between April–December 2021 in Italy |
title_short | Epidemiological and Clinical Features of SARS-CoV-2 Variants Circulating between April–December 2021 in Italy |
title_sort | epidemiological and clinical features of sars-cov-2 variants circulating between april–december 2021 in italy |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9699621/ https://www.ncbi.nlm.nih.gov/pubmed/36423117 http://dx.doi.org/10.3390/v14112508 |
work_keys_str_mv | AT laialessia epidemiologicalandclinicalfeaturesofsarscov2variantscirculatingbetweenaprildecember2021initaly AT bergnaannalisa epidemiologicalandclinicalfeaturesofsarscov2variantscirculatingbetweenaprildecember2021initaly AT dellaventuracarla epidemiologicalandclinicalfeaturesofsarscov2variantscirculatingbetweenaprildecember2021initaly AT menzostefano epidemiologicalandclinicalfeaturesofsarscov2variantscirculatingbetweenaprildecember2021initaly AT bruzzonebianca epidemiologicalandclinicalfeaturesofsarscov2variantscirculatingbetweenaprildecember2021initaly AT sagradifabio epidemiologicalandclinicalfeaturesofsarscov2variantscirculatingbetweenaprildecember2021initaly AT ceccherinisilbersteinfrancesca epidemiologicalandclinicalfeaturesofsarscov2variantscirculatingbetweenaprildecember2021initaly AT weiszalessandro epidemiologicalandclinicalfeaturesofsarscov2variantscirculatingbetweenaprildecember2021initaly AT clementinicola epidemiologicalandclinicalfeaturesofsarscov2variantscirculatingbetweenaprildecember2021initaly AT brindiccigaetano epidemiologicalandclinicalfeaturesofsarscov2variantscirculatingbetweenaprildecember2021initaly AT vicentiilaria epidemiologicalandclinicalfeaturesofsarscov2variantscirculatingbetweenaprildecember2021initaly AT sassetlolita epidemiologicalandclinicalfeaturesofsarscov2variantscirculatingbetweenaprildecember2021initaly AT cauccisara epidemiologicalandclinicalfeaturesofsarscov2variantscirculatingbetweenaprildecember2021initaly AT corvarobenedetta epidemiologicalandclinicalfeaturesofsarscov2variantscirculatingbetweenaprildecember2021initaly AT ippolitisilvia epidemiologicalandclinicalfeaturesofsarscov2variantscirculatingbetweenaprildecember2021initaly AT acciarricarla epidemiologicalandclinicalfeaturesofsarscov2variantscirculatingbetweenaprildecember2021initaly AT depacevanessa epidemiologicalandclinicalfeaturesofsarscov2variantscirculatingbetweenaprildecember2021initaly AT lanfranchileonardo epidemiologicalandclinicalfeaturesofsarscov2variantscirculatingbetweenaprildecember2021initaly AT bellocchimariac epidemiologicalandclinicalfeaturesofsarscov2variantscirculatingbetweenaprildecember2021initaly AT giuratogiorgio epidemiologicalandclinicalfeaturesofsarscov2variantscirculatingbetweenaprildecember2021initaly AT ferrareseroberto epidemiologicalandclinicalfeaturesofsarscov2variantscirculatingbetweenaprildecember2021initaly AT lagioiaantonella epidemiologicalandclinicalfeaturesofsarscov2variantscirculatingbetweenaprildecember2021initaly AT franciscidaniela epidemiologicalandclinicalfeaturesofsarscov2variantscirculatingbetweenaprildecember2021initaly AT colombomartinal epidemiologicalandclinicalfeaturesofsarscov2variantscirculatingbetweenaprildecember2021initaly AT lazzarinsamuel epidemiologicalandclinicalfeaturesofsarscov2variantscirculatingbetweenaprildecember2021initaly AT ogliastromatilde epidemiologicalandclinicalfeaturesofsarscov2variantscirculatingbetweenaprildecember2021initaly AT cappellettimariar epidemiologicalandclinicalfeaturesofsarscov2variantscirculatingbetweenaprildecember2021initaly AT iannettamarco epidemiologicalandclinicalfeaturesofsarscov2variantscirculatingbetweenaprildecember2021initaly AT rizzofrancesca epidemiologicalandclinicalfeaturesofsarscov2variantscirculatingbetweenaprildecember2021initaly AT torticarlo epidemiologicalandclinicalfeaturesofsarscov2variantscirculatingbetweenaprildecember2021initaly AT fumimaurizio epidemiologicalandclinicalfeaturesofsarscov2variantscirculatingbetweenaprildecember2021initaly AT daveniamorena epidemiologicalandclinicalfeaturesofsarscov2variantscirculatingbetweenaprildecember2021initaly AT brusastefano epidemiologicalandclinicalfeaturesofsarscov2variantscirculatingbetweenaprildecember2021initaly AT grecofrancesca epidemiologicalandclinicalfeaturesofsarscov2variantscirculatingbetweenaprildecember2021initaly AT menchiseangela epidemiologicalandclinicalfeaturesofsarscov2variantscirculatingbetweenaprildecember2021initaly AT letiziavittoria epidemiologicalandclinicalfeaturesofsarscov2variantscirculatingbetweenaprildecember2021initaly AT vaccaroemilia epidemiologicalandclinicalfeaturesofsarscov2variantscirculatingbetweenaprildecember2021initaly AT santorocarmenr epidemiologicalandclinicalfeaturesofsarscov2variantscirculatingbetweenaprildecember2021initaly AT fraccalvierichiara epidemiologicalandclinicalfeaturesofsarscov2variantscirculatingbetweenaprildecember2021initaly AT testasophie epidemiologicalandclinicalfeaturesofsarscov2variantscirculatingbetweenaprildecember2021initaly AT cariotiluca epidemiologicalandclinicalfeaturesofsarscov2variantscirculatingbetweenaprildecember2021initaly AT roccoteresa epidemiologicalandclinicalfeaturesofsarscov2variantscirculatingbetweenaprildecember2021initaly AT saracinoannalisa epidemiologicalandclinicalfeaturesofsarscov2variantscirculatingbetweenaprildecember2021initaly AT cattelanannamaria epidemiologicalandclinicalfeaturesofsarscov2variantscirculatingbetweenaprildecember2021initaly AT clementimassimo epidemiologicalandclinicalfeaturesofsarscov2variantscirculatingbetweenaprildecember2021initaly AT sarmatiloredana epidemiologicalandclinicalfeaturesofsarscov2variantscirculatingbetweenaprildecember2021initaly AT rivaagostino epidemiologicalandclinicalfeaturesofsarscov2variantscirculatingbetweenaprildecember2021initaly AT gallimassimo epidemiologicalandclinicalfeaturesofsarscov2variantscirculatingbetweenaprildecember2021initaly AT antinorispinello epidemiologicalandclinicalfeaturesofsarscov2variantscirculatingbetweenaprildecember2021initaly AT zehendergianguglielmo epidemiologicalandclinicalfeaturesofsarscov2variantscirculatingbetweenaprildecember2021initaly AT epidemiologicalandclinicalfeaturesofsarscov2variantscirculatingbetweenaprildecember2021initaly |